Detalhe da pesquisa
1.
Pharmacodynamics of selective inhibition of γ-secretase by avagacestat.
J Pharmacol Exp Ther
; 344(3): 686-95, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23275065
2.
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
Br J Clin Pharmacol
; 75(1): 136-45, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22616739
3.
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.
Clin Ther
; 34(3): 654-67, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22381714
4.
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects.
Clin Pharmacokinet
; 51(10): 681-93, 2012 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23018531
5.
Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aß levels in healthy young men.
Clin Drug Investig
; 32(11): 761-9, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23018285
6.
Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
Clin Pharmacokinet
; 50(4): 253-65, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21348538